A Novel Proteogenomic Integration Strategy Expands the Breadth of Neo-Epitope Sources.

Abstract

Tumor-specific antigens can activate T cell-based antitumor immune responses and are ideal targets for cancer immunotherapy. However, their identification is still challenging. Although mass spectrometry can directly identify human leukocyte antigen (HLA) binding peptides in tumor cells, it focuses on tumor-specific antigens derived from annotated protein-coding regions constituting only 1.5% of the genome. We developed a novel proteogenomic integration strategy to expand the breadth of tumor-specific epitopes derived from all genomic regions. Using the colorectal cancer cell line HCT116 as a model, we accurately identified 10,737 HLA-presented peptides, 1293 of which were non-canonical peptides that traditional database searches could not identify. Moreover, we found eight tumor neo-epitopes derived from somatic mutations, four of which were not previously reported. Our findings suggest that this new proteogenomic approach holds great promise for increasing the number of tumor-specific antigen candidates, potentially enlarging the tumor target pool and improving cancer immunotherapy.

• Authors: Haitao Xiang, Le Zhang, Fanyu Bu, Xiangyu Guan, Lei Chen, Haibo Zhang, Yuntong Zhao, Huanyi Chen, Weicong Zhang, Yijian Li, Leo Jingyu Lee, Zhanlong Mei, Yuan Rao, Ying Gu, Yong Hou, Feng Mu, Xuan Dong
• Journal: Cancers (Cancers (Basel)) Vol. 14 Issue 12 (Jun 19 2022) ISSN: 2072-6694 [Print] Switzerland
• PMID: 35740681 (Publication Type: Journal Article)